Search

Immunobiology / Immunotherapy of H&N Cancer

B046

ANTI-OX-40 (MEDI6469) PRIOR TO DEFINITIVE SURGICAL RESECTION IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunobiology / Immunotherapy of H&N Cancer

R. Bryan Bell, MD, DDS, FACS1, Rom S Leidner, MD1, Zipei Feng, MD, PhD2, Rebekka Duhen, PhD1, Yoshi Koguchi, PhD1, Carlo Bifulco, MD1, Bernard A Fox, PhD1, Brendan Curti, MD1, Andrew D Weinberg, PhD1

1Earle A. Chiles Research Institute at Providence Cancer Center, 2Oregon Health & Science University


B047

THE ROLE OF TLR3 SIGNALING IN CHEMORESISTANCE OF HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunobiology / Immunotherapy of H&N Cancer

Hui-Ching Chuang, MD, PhD

Kaoshiung Chang Gung Memorial Hospital


B048

LOSS OF PROTECTIVE CD169 MACROPHAGES IN LYMPH NODES WITH METASTATIC SQUAMOUS CELL CARCINOMA WITH PRESERVATION IN ADJACENT NEGATIVE DRAINING LYMPH NODES

Immunobiology / Immunotherapy of H&N Cancer

Michael C Topf, MD, Christopher M Shumrick, BS, Madalina Tuluc, MD, David M Cognetti, MD, Joseph M Curry, MD, Adam Luginbuhl, MD

Thomas Jefferson University Hospital


B049

CETUXIMAB AND CISPLATIN EFFECTS ON OROSPHERE FORMATION AND GENE EXPRESSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) CELLS: THE POTENTIAL FOR A PROGNOSTIC BIOMARKER

Immunobiology / Immunotherapy of H&N Cancer

Valeda Yong, BA1, Lechuang Chen, MD, PhD2, Ashlee Jeter, BS2, Chad Zender, MD, FACS3, Ge Jin, PhD2, Aaron Weinberg, DMD, PhD2

1Case Western Reserve University School of Medicine, 2Case Western Reserve School of Dental Medicine - Biological Sciences, 3University Hospitals Cleveland Medical Center - ENT Institute